TNG-462 is an orally active PRMT5 inhibitor for investigation of MTAP-deficient and/or MTA-accumulating cancers.
TNG908 is a PRMT5 inhibitor that crosses the blood-brain barrier and can be used in studies related to advanced solid tumors.
TNG908 is a PRMT5 inhibitor that crosses the blood-brain barrier and can be used in studies related to advanced solid tumors.
TNG908 is a PRMT5 inhibitor that crosses the blood-brain barrier and can be used in studies related to advanced solid tumors.
TNO155 is a first-in-class, selective, orally active wild-type SHP2 metamorphosis inhibitor with an IC50 value of 0.011 µM. tNO155 has good water solubility (0.736 mM), moderate lipophilicity (LogP=1.6), high lipophilic efficiency (>6), and no hERG inhibition (IC50 >30 μM) and no phototoxicity. Does not inhibit CYP450.